The United States Food and Drug Administration (USFDA) has given Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) final approval to market Ivermectin Cream, 1%.
Ivermectin Cream is used in the treatment of rosacea’s inflammatory lesions. The medication will be produced at the group’s topical manufacturing facility in Ahmedabad, India.
According to IQVIA MAT June 2022 data, Ivermectin Cream had annual sales of USD 176 million in the United States.
Since the beginning of the filing process in FY 2003-04, the group has received 319 approvals and has filed over 420* ANDAs.
Zydus Lifesciences was trading at Rs357.80 up by 3.31% from its previous closing of Rs346.35 on the BSE. The scrip touched intraday high and low of Rs358.65 and Rs346.10 respectively.